Board of Directors
MDxHealth was established by a management staff with extensive biotechnology industry experience.
Mr. Edward L. Erickson
Chairman of the Board, Independent Director
Mr. Erickson has extensive executive and board level experience in diagnostics, therapeutics, and life science research products having served as president, CEO or a director of over a dozen companies in these industries. Most recently, he served as president and CEO of Saladax Biomedical, Inc., a diagnostics company specializing in companion diagnostic and therapeutic dose management assays.
Prior to joining Saladax, he served as interim president and CEO of BioNanomatrix, Inc., a privately held genomics company developing and commercializing proprietary DNA analysis systems. Previously, he was Chairman, President and CEO of Cellatope Corporation, a private company developing diagnostic products in the field of autoimmune diseases. Prior to this, he served in top leadership roles, including president, CEO and/or chairman, of three venture-capital backed medical products companies, Cholestech (diagnostics), DepoTech (pharmaceuticals/drug delivery) and Immunicon (diagnostics), which successfully completed initial public offerings under his leadership. Earlier in his career, he held senior executive positions at The Ares-Serono Group (now Merck Serono, S.A.) and Amersham International (acquired by GE). Mr. Erickson is currently non-executive chairman of MDxHealth, S.A., a molecular diagnostics company, a director of Saladax, and serves as an advisor to entrepreneurial companies. His board committee experience includes chairmanship/membership in the Audit, Compensation, Nominating & Governance and Transaction (M&A) committees of public and private corporations. Early in his career he worked in the fields of information technology, energy and natural resources and defense systems.
Mr. Erickson holds an MBA with high distinction from the Harvard Graduate School of Business Administration, where he was elected a Baker Scholar and was awarded the Loeb Rhoades Fellowship in Finance, and B.S. and M.S. degrees in Mathematics from the Illinois Institute of Technology. He did military service as an officer in the U.S. Navy’s nuclear submarine force, including active duty aboard the USS Nautilus (SSN-571), the world’s first nuclear submarine.
Mr. Raphael Wisniewski
Director, representing Edmond de Rothschild Investment Partners
Mr. Raphael Wisniewski is a Partner at Edmond de Rothschild Investment Partners. Previously, Mr. Wisniewski was an Associate at Goldman Sachs Group and Salomon Smith Barney, Inc. and worked at Générale de Santé International.
He is a Director at Pamgene International BV, Poxel SA, Nautilus Biotech, and Novagali Pharma. Mr. Wisniewski holds a degree from HEC and a D.E.A. in Economics and Finance from IEP Paris.
Mrs.Ruth Devenyns
Independent Director
Mrs. Devenyns is an Investment Director at Korys since June 2012. She is part of the Direct Investments team, with a primary focus on life sciences. Mrs. Devenyns has a long standing experience in the biotechnology sector. Former analyst and investment banker, she was in charge of the venture capital activities in the sector at KBC Private Equity until end of March 2012.
Mrs. Devenyns was involved in several IPO’s, private placements and M&A-transactions and held various directorships including Ablynx, Applied Maths and Pronota. At KBC Private Equity she also managed various investments in agro-biotech and seed companies such as CropDesign and Ceres. Currently, Mrs. Devenyns is an independent director in 2 Euronext-listed companies (MDxHealth and Devgen) and director of FlandersBio, the biotech sector organization in Flanders.
Dr. Jan Groen
CEO (Executive member of the Board)
Dr. Jan Groen joined MDxHealth in 2010 and has more than 25 years of experience in the clinical diagnostic industry, with a particular focus on emerging technologies, product development and commercialization.
Dr. Groen was previously the president of Agendia, Inc. and COO of Agendia B.V., responsible for their United States and European diagnostic operations, respectively. Prior to this, he served as VP of Research & Development at Focus Diagnostics, Inc., a subsidiary of Quest Diagnostics, in California. Dr. Groen has held numerous management and scientific positions at ViroClinics B.V., the Erasmus Medical Center, and Akzo-Nobel. Dr. Jan Groen is a supervisory board member of IBL International B.V. Dr. Groen holds a Ph.D. degree from the Erasmus University Rotterdam and published more than 125 papers in international scientific journals in the field of clinical diagnostics.
Mr. Rudi Mariën
Director, representing Biovest CVA
Mr. Mariën is currently Director of Biocartis S.A. (Swirtzeland). He is also President and CEO of Gengest Bvba and Biovest CommVa.
Through his management company, Gengest BVBA, Mr. Mariën has board mandates in different stock listed (Quest For Growth, Devgen... ) and private biotech companies (ActogenixNV, Pharmaneuroboost NV, Oystershell NV…).
Previously Mr. Mariën was founder, reference shareholder and managing director of Barc NV group, a leading international centralized clinical laboratory, exclusively dedicated to pharmaceuticals studies.
He was also the co-founder, reference shareholder and chairman of the biotech company Innogenetics NV.
Mr. Mark Myslinski
Independent Director
Mr. Myslinski currently serves as Chief Commercial Officer for Saladax Biomedical, Inc. Previously, Mr. Myslinski was CEO of RedPath Integrated Pathology, Inc. and Rapid Pathogen Screening, Inc. Mr. Myslinski has experience in commercializing novel cancer tests to the clinical community and his background spans early stage diagnostic companies to Fortune 100 companies.
Mr. Myslinski was a Johnson & Johnson executive where his responsibilities included building a new, worldwide Evidence-Based Medicine function for the Ortho-Clinical Diagnostics unit. For five years, Mr. Myslinski was General Manager of Johnson & Johnson's Veridex, LLC, a division focused on molecular and cellular diagnostics that achieved rapid sales growth under Mr. Myslinski's tenure. Mr. Myslinski also held executive roles in the venture-backed start-ups Interscope Technologies and Precision Therapeutics, both focused on the field of pathology with an emphasis on cancer. Prior to joining Johnson & Johnson, Mr. Myslinski held several senior leadership positions in the health care industry, spanning 25 years, including a variety of positions in the life sciences and the in vitro diagnostics industries. His experience is predominantly in General Management.
Dr. Karin Dorrepaal
Director
Dr. Dorrepaal was in 2011 on the Supervisory Board of Ergo Versicherungsgruppe and on the advisory committees of Triton Private Equity.
Dr. Karin Louise Dorrepaal received her Ph.D. in medicine from the Free University of Amsterdam and her MBA from the Erasmus University Rotterdam School of Management.
Until 2004, Dr. Dorrepaal was vice-president of Booz and Company, Management Consultants, where she specialized in the pharmaceutical industry and advised on issues regarding strategy, sales, marketing and supply chain.
From 2004 until 2006, Dr. Dorrepaal served on the executive board of Schering AG, where she was responsible for Schering’s Global Business Unit Diagnostic Imaging and Supply Chain and Procurement.